34604280|t|APOE Genotype Modifies the Plasma Oxylipin Response to Omega-3 Polyunsaturated Fatty Acid Supplementation in Healthy Individuals.
34604280|a|The omega-3 polyunsaturated fatty acids (n-3 PUFAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), mediate inflammation in large part by affecting pro-inflammatory and anti-inflammatory/pro-resolving oxylipin concentrations. Common gene variants are thought to underlie the large inter-individual variation in oxylipin levels in response to n-3 PUFA supplementation, which in turn is likely to contribute to the overall heterogeneity in response to n-3 PUFA intervention. Given its known role in inflammation and as a modulator of the physiological response to EPA and DHA, here we explore, for the first time, the differential response of plasma hydroxy-, epoxy- and dihydroxy-arachidonic acid, EPA and DHA oxylipins according to apolipoprotein E (APOE) genotype using samples from a dose-response parallel design RCT. Healthy participants were given doses of EPA+DHA equivalent to intakes of 1, 2, and 4 portions of oily fish per week for 12 months. There was no difference in the plasma levels of EPA, DHA or ARA between the wildtype APOE3/E3 and APOE4 carrier groups after 3 or 12 months of n-3 PUFA supplementation. At 12 months, hydroxy EPAs (HEPEs) and hydroxy-DHAs (HDHAs) were higher in APOE4 carriers, with the difference most evident at the highest EPA+DHA intake. A significant APOE*n-3 PUFA dose effect was observed for the CYP-omega hydroxylase products 19-HEPE (p = 0.027) and 20-HEPE (p = 0.011). 8-HEPE, which, along with several other plasma oxylipins, is an activator of peroxisome proliferator activated receptors (PPARs), showed the highest fold change in APOE4 carriers (14-fold) compared to APOE3/E3 (4-fold) (p = 0.014). Low basal plasma EPA levels (EPA < 0.85% of total fatty acids) were associated with a greater change in 5-HEPE, 9-HEPE, 11-HEPE, and 20-HEPE compared to high basal EPA levels (EPA > 1.22% of total fatty acids). In conclusion, APOE genotype modulated the plasma oxylipin response to increased EPA+DHA intake, with APOE4 carriers presenting with the greatest increases following high dose n-3 PUFA supplementation for 12 months.
34604280	0	4	APOE	Gene	348
34604280	55	89	Omega-3 Polyunsaturated Fatty Acid	Chemical	MESH:D015525
34604280	134	169	omega-3 polyunsaturated fatty acids	Chemical	MESH:D015525
34604280	171	180	n-3 PUFAs	Chemical	MESH:D015525
34604280	183	204	eicosapentaenoic acid	Chemical	MESH:D015118
34604280	206	209	EPA	Chemical	MESH:D015118
34604280	215	235	docosahexaenoic acid	Chemical	MESH:D004281
34604280	237	240	DHA	Chemical	MESH:D004281
34604280	251	263	inflammation	Disease	MESH:D007249
34604280	295	307	inflammatory	Disease	MESH:D007249
34604280	317	329	inflammatory	Disease	MESH:D007249
34604280	344	352	oxylipin	Chemical	MESH:D054883
34604280	485	493	n-3 PUFA	Chemical	MESH:D015525
34604280	593	601	n-3 PUFA	Chemical	MESH:D015525
34604280	640	652	inflammation	Disease	MESH:D007249
34604280	705	708	EPA	Chemical	MESH:D015118
34604280	713	716	DHA	Chemical	MESH:D004281
34604280	791	838	hydroxy-, epoxy- and dihydroxy-arachidonic acid	Chemical	-
34604280	840	843	EPA	Chemical	MESH:D015118
34604280	848	851	DHA	Chemical	MESH:D004281
34604280	852	861	oxylipins	Chemical	MESH:D054883
34604280	875	891	apolipoprotein E	Gene	348
34604280	893	897	APOE	Gene	348
34604280	1005	1008	EPA	Chemical	MESH:D015118
34604280	1009	1012	DHA	Chemical	MESH:D004281
34604280	1144	1147	EPA	Chemical	MESH:D015118
34604280	1149	1152	DHA	Chemical	MESH:D004281
34604280	1156	1159	ARA	Chemical	MESH:D016718
34604280	1181	1186	APOE3	Gene	348
34604280	1194	1199	APOE4	Gene	348
34604280	1239	1247	n-3 PUFA	Chemical	MESH:D015525
34604280	1279	1291	hydroxy EPAs	Chemical	-
34604280	1293	1298	HEPEs	Chemical	MESH:D006531
34604280	1304	1316	hydroxy-DHAs	Chemical	-
34604280	1318	1323	HDHAs	Chemical	-
34604280	1340	1345	APOE4	Gene	348
34604280	1404	1407	EPA	Chemical	MESH:D015118
34604280	1408	1411	DHA	Chemical	MESH:D004281
34604280	1512	1519	19-HEPE	Chemical	-
34604280	1536	1543	20-HEPE	Chemical	-
34604280	1557	1563	8-HEPE	Chemical	-
34604280	1604	1613	oxylipins	Chemical	MESH:D054883
34604280	1721	1726	APOE4	Gene	348
34604280	1758	1763	APOE3	Gene	348
34604280	1806	1809	EPA	Chemical	MESH:D015118
34604280	1818	1821	EPA	Chemical	MESH:D015118
34604280	1839	1850	fatty acids	Chemical	MESH:D005227
34604280	1893	1899	5-HEPE	Chemical	MESH:C058722
34604280	1901	1907	9-HEPE	Chemical	-
34604280	1909	1916	11-HEPE	Chemical	-
34604280	1922	1929	20-HEPE	Chemical	-
34604280	1953	1956	EPA	Chemical	MESH:D015118
34604280	1965	1968	EPA	Chemical	MESH:D015118
34604280	1986	1997	fatty acids	Chemical	MESH:D005227
34604280	2015	2019	APOE	Gene	348
34604280	2050	2058	oxylipin	Chemical	MESH:D054883
34604280	2081	2084	EPA	Chemical	MESH:D015118
34604280	2085	2088	DHA	Chemical	MESH:D004281
34604280	2102	2107	APOE4	Gene	348
34604280	2176	2184	n-3 PUFA	Chemical	MESH:D015525
34604280	Positive_Correlation	MESH:D004281	MESH:D006531
34604280	Association	MESH:C058722	348
34604280	Association	MESH:D015118	MESH:D007249
34604280	Association	MESH:D004281	MESH:D054883
34604280	Negative_Correlation	MESH:D054883	MESH:D007249
34604280	Association	MESH:D015525	348
34604280	Association	MESH:D006531	348
34604280	Association	MESH:D004281	MESH:D007249
34604280	Association	MESH:D015525	MESH:D054883
34604280	Association	MESH:D015118	348
34604280	Comparison	MESH:D004281	MESH:D015118
34604280	Association	MESH:D007249	348
34604280	Association	MESH:D054883	348
34604280	Association	MESH:D015525	MESH:D007249
34604280	Association	MESH:D015118	MESH:D054883

